Skip to main content

Advertisement

SpringerLink
Log in

Effect of continuous long-term treatment for 10 years with bisphosphonate on Japanese osteoporosis patients

  • Original Article
  • Published:
Journal of Bone and Mineral Metabolism Aims and scope Submit manuscript

Abstract

Introduction

In terms of the balance between benefits and risks of long-term treatment with bisphosphonate, uncertainties remain regarding the optimal treatment duration. We investigated effects of continuous long-term treatment for 10 years with bisphosphonate in postmenopausal osteoporosis patients.

Materials and methods

Fifty five patients in the outpatient clinic of our hospital have been continuously treated with alendronate or risedronate for 10 years. All data were retrospectively collected. The age, height, weight, total muscle volume, total fat volume, and BMD at the lumbar spine, total hip and distal 1/3 radius, alkaline phosphatase (ALP), urinary type I collagen cross-linked N-telopeptide (uNTX) and tartrate-resistant acid phosphatase-5b (TRAP5b), calcium (Ca) and phosphate (P) levels were measured pre- and after the start of 10-year continuous treatment.

Results

BMD at the lumbar spine increased continuously over the 10-year period, while BMD at the total hip slightly but significantly decreased, and that at the 1/3 radius did not show any significant change over the 10 years. Serum Ca value was significantly decreased after the start of treatment, and became stable within the reference range from the second year. Bone resorption markers such as uNTX and TRAP5b significantly decreased from the second year after the start of treatment and no significant changes were observed thereafter. There were no serious medical adverse events including atypical femoral fractures and osteonecrosis of the jaw.

Conclusion

We believe that the continuous use of alendronate and risedronate for 10 years could be an option for the treatment of postmenopausal osteoporosis patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7

Similar content being viewed by others

References

  1. Wells GA, Cranney A, Peterson J, Boucher M, Shea B, Robinson V, Coyle D, Tugwell P (2008) Alendronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women. Cochrane Database Syst Rev 23:CD001155

    Google Scholar 

  2. Cranney A, Tugwell P, Adachi J, Weaver B, Zytaruk N, Papaioannou A, Robinson V, Shea B, Wells G, Guyatt G, Osteoporosis Methodology Group and The Osteoporosis Research Advisory Group (2002) Meta-analyses of therapies for postmenopausal osteoporosis. III. Meta-analysis of risedronate for the treatment of postmenopausal osteoporosis. Endocr Rev 23:517–523

    Article  CAS  Google Scholar 

  3. Shane E, Burr D, Abrahamsen B, Adler RA, Brown TD, Cheung AM, Cosman F, Curtis JR, Dell R, Dempster DW, Ebeling PR (2014) Atypical subtrochanteric and diaphyseal femoral fractures: second report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 29:1–23

    Article  Google Scholar 

  4. Chen JS, Sambrock PN (2011) Antiresorptive therapies for osteoporosis: a clinical overview. Nat Rev Endocrinol 8:81–91

    Article  Google Scholar 

  5. Black DM, Schwartz AV, Ensrud KE, Cauley JA, Levis S, Quandt SA, Satterfield S, Wallace RB, Bauer DC, Palermo L, Wehren LE (2006) Effects of continuing or stopping alendronate after 5 years treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial. JAMA 296:2927–2938

    Article  CAS  Google Scholar 

  6. Adler RA, El‐Hajj Fuleihan G, Bauer DC, Camacho PM, Clarke BL, Clines GA, Compston JE, Drake MT, Edwards BJ, Favus MJ, Greenspan SL (2016) Managing osteoporosis in patients on long-term bisphosphonate treatment: report of task force of the American Society for Bone and Mineral Research. J Bone Miner Res 31:16–35

    Article  CAS  Google Scholar 

  7. Abrahamsen B, Eiken P, Prieto-Alhambra D, Eastell R (2016) Risk of hip, subtrochanteric, and femoral shaft fractures among mid and long term users of alendronate: nationwide cohort and nested case-control study. BMJ 353:i3365

    Article  Google Scholar 

  8. Orimo H, Hayashi Y, Fukunaga M, Sone T, Fujiwara S, Shiraki M, Kushida K, Miyamoto S, Soen S, Nishimura J, Oh-Hashi Y, Hosoi T, Gorai I, Tanaka H, Igai T, Kishimoto H, Osteoporosis Diagnostic Criteria Review Committee: Japanese Society for Bone and Mineral Research (2001) Diagnostic criteria for primary osteoporosis: year 2000 revision. J Bone Miner Metab 19:331–337

    Article  CAS  Google Scholar 

  9. Khan AA, Morrison A, Hanley DA, Felsenberg D, McCauley LK, O’Ryan F, Reid IR, Ruggiero SL, Taguchi A, Tetradis S, Watts NB (2015) International task force on osteonecrosis of the Jaw. Diagnosis and management of osteonecrosis of the jaw: a systematic review and international consensus. J Bone Miner Res 30:3–23

    Article  Google Scholar 

  10. Schilcher J, Koeppen V, Aspenberg P, Michaëlsson K (2015) Risk of atypical femoral fracture during and after bisphosphonate use. Acta Orthop 86:100–107

    Article  Google Scholar 

  11. Dell RM, Adams AL, Greene DF, Funahashi TT, Silverman SL, Eisemon EO, Zhou H, Burchette RJ, Ott SM (2012) Incidence of atypical nontraumatic diaphyseal fractures of the femur. J Bone Miner Res 27:2544–2550

    Article  Google Scholar 

  12. Edwards BJ, Bunta AD, Lane J, Odvina C, Rao DS, Raisch DW, McKoy JM, Omar I, Belknap SM, Garg V, Hahr AJ (2013) Bisphosphonate and nonhealing femoral fractures: analysis of the FDA Adverse Event Reporting System (FAERS) and international safety efforts: a systematic review from the Research on Adverse Drug Events And Reports (RADAR) project. J Bone Joint Surg Am 95:297–307

    Article  Google Scholar 

  13. Campos-Obando N, Koek WNH, Hooker ER, van der Eerden BC, Pols HA, Hofman A, van Leeuwen JP, Uitterlinden AG, Nielson CM, Zillikens MC (2017) Serum phosphate is associated with fracture risk: the rotterdam study and MrOS. J Bone Miner Res 32:1182–1193

    Article  CAS  Google Scholar 

  14. Axelsson KF, Wallander M, Johansson H, Lundh D, Lorentzon M (2017) Hip fracture risk and safety with alendronate treatment in the oldest-old. J Intern Med 282:546–559

    Article  CAS  Google Scholar 

  15. Cummings SR, Cosman F, Lewiecki EM, Schousboe JT, Bauer DC et al (2017) Goal-directed treatment for osteoporosis: a progress report from the ASBMR-NOF working group on goal-directed treatment for osteoporosis. J Bone Miner Res 32:3–10

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Orthopaedic Surgery, Sapporo Medical University School of Medicine, South-1, West-16, Chuo-ku, Sapporo, 060-8543, Japan

    Kousuke Iba & Toshihiko Yamashita

  2. Kitago Orthopaedic Clinic, Sapporo, Japan

    Junichi Takada

  3. Department of Public Health, Sapporo Medical University School of Medicine, Sapporo, 060-8543, Japan

    Tomoko Sonoda

Authors
  1. Kousuke Iba
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Junichi Takada
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Tomoko Sonoda
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Toshihiko Yamashita
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

KI: study design, treatment of the patients, measurements of the parameters, and manuscript preparation. JT: treatment of the patients, measurements of the parameters, and manuscript preparation. TS: statistical analysis and manuscript preparation. TY: study design and manuscript preparation.

Corresponding author

Correspondence to Kousuke Iba.

Ethics declarations

Conflict of interest

No authors have any potential conflicts of interest to declare.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Iba, K., Takada, J., Sonoda, T. et al. Effect of continuous long-term treatment for 10 years with bisphosphonate on Japanese osteoporosis patients. J Bone Miner Metab 38, 240–247 (2020). https://doi.org/10.1007/s00774-019-01049-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00774-019-01049-1

Keywords

Search

Navigation